Physician profile
Thelma M Campbell
NPI 1093801755
$757.32
in general payments reported to CMS, 2019-2025
11 companies · $146 in 2025
The $146 reported for 2025 was more than what 80% of Obstetric, High-Risk providers received nationally (typical 2025 total: $93.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.89 · 2022: $217 · 2023: $168 · 2024: $161 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $474.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $181.82 | 2021-2022 | |
| Biogen, INC. | $146.16 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $115.93 | 2023 | Myfembree |
| Hologic Sales and Service, LLC | $81.31 | 2022-2024 | Aptima |
| Astellas Pharma US INC | $61.82 | 2024 | Veozah |
| Ethicon US, LLC | $42.82 | 2024 | Dermabond Prineo, Ethicon, Enseal |
| Exeltis, USA INC. | $38.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.23 | 2024 | |
| Myovant Sciences INC. | $29.12 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $13.54 | 2023 | Seglentis |
| Avion Pharmaceuticals | $13.25 | 2023 | Balcoltra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thelma Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.